Correlation of biomarkers of endothelium dysfunction and matrix remodeling in patients with systemic sclerosis.
Standard
Correlation of biomarkers of endothelium dysfunction and matrix remodeling in patients with systemic sclerosis. / Blaise, Sophie; Maas, Renke; Trocme, Candice; Kom, Ghainsom D; Roustit, Matthieu; Carpentier, Patrick H; Cracowski, Jean-Luc.
in: J RHEUMATOL, Jahrgang 36, Nr. 5, 5, 2009, S. 984-988.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Correlation of biomarkers of endothelium dysfunction and matrix remodeling in patients with systemic sclerosis.
AU - Blaise, Sophie
AU - Maas, Renke
AU - Trocme, Candice
AU - Kom, Ghainsom D
AU - Roustit, Matthieu
AU - Carpentier, Patrick H
AU - Cracowski, Jean-Luc
PY - 2009
Y1 - 2009
N2 - OBJECTIVE: Systemic sclerosis (SSc) is a multisystem disease characterized by microvascular dysfunction and excessive fibrosis. However, the relationship between these 2 features remains unclear. Endothelial dysfunction can be assessed by quantifying plasma asymmetric dimethylarginine (ADMA), an endogenous inhibitor of endothelial nitric oxide synthase. Matrix remodeling can be assessed by quantifying serum tissue inhibitor of matrix metalloproteinases-1 (TIMP-1). Both biomarkers are elevated in patients with SSc. Our objective was to test whether plasma ADMA is correlated with serum TIMP-1. METHODS: We enrolled 91 subjects, 39 patients with SSc, 28 patients with primary Raynaud's phenomenon (RP), and 24 healthy volunteers. Plasma ADMA concentrations were measured by liquid chromatography-tandem mass spectrometry. Serum TIMP-1 concentrations were determined by ELISA. RESULTS: Mean ADMA concentrations were higher in patients with SSc (0.68 microM +/- 0.12) than in patients with primary RP or healthy volunteers (respectively, 0.56 microM +/- 0.14 and 0.62 microM +/- 0.12; p = 0.002). Median serum TIMP-1 concentrations were increased in patients with SSc compared to primary RP and healthy volunteers [12 (9-15), 11 (8-13), and 10 (7-13) nM, respectively; p = 0.05]. In the SSc group, we observed a statistically significant correlation between plasma ADMA and serum TIMP-1 (r = 0.34, p = 0.035). CONCLUSION: These data are consistent with our hypothesis of an association of endothelial dysfunction and matrix remodeling in scleroderma spectrum disorders.
AB - OBJECTIVE: Systemic sclerosis (SSc) is a multisystem disease characterized by microvascular dysfunction and excessive fibrosis. However, the relationship between these 2 features remains unclear. Endothelial dysfunction can be assessed by quantifying plasma asymmetric dimethylarginine (ADMA), an endogenous inhibitor of endothelial nitric oxide synthase. Matrix remodeling can be assessed by quantifying serum tissue inhibitor of matrix metalloproteinases-1 (TIMP-1). Both biomarkers are elevated in patients with SSc. Our objective was to test whether plasma ADMA is correlated with serum TIMP-1. METHODS: We enrolled 91 subjects, 39 patients with SSc, 28 patients with primary Raynaud's phenomenon (RP), and 24 healthy volunteers. Plasma ADMA concentrations were measured by liquid chromatography-tandem mass spectrometry. Serum TIMP-1 concentrations were determined by ELISA. RESULTS: Mean ADMA concentrations were higher in patients with SSc (0.68 microM +/- 0.12) than in patients with primary RP or healthy volunteers (respectively, 0.56 microM +/- 0.14 and 0.62 microM +/- 0.12; p = 0.002). Median serum TIMP-1 concentrations were increased in patients with SSc compared to primary RP and healthy volunteers [12 (9-15), 11 (8-13), and 10 (7-13) nM, respectively; p = 0.05]. In the SSc group, we observed a statistically significant correlation between plasma ADMA and serum TIMP-1 (r = 0.34, p = 0.035). CONCLUSION: These data are consistent with our hypothesis of an association of endothelial dysfunction and matrix remodeling in scleroderma spectrum disorders.
KW - Humans
KW - Male
KW - Female
KW - Middle Aged
KW - inhibitors
KW - derivatives
KW - Arginine analogs
KW - Biological Markers metabolism
KW - Endothelium, Vascular metabolism
KW - Enzyme Inhibitors metabolism
KW - Extracellular Matrix metabolism
KW - Nitric Oxide Synthase antagonists
KW - Raynaud Disease metabolism
KW - Regional Blood Flow physiology
KW - Scleroderma, Systemic metabolism
KW - Skin blood supply
KW - Tissue Inhibitor of Metalloproteinase-1 metabolism
KW - Humans
KW - Male
KW - Female
KW - Middle Aged
KW - inhibitors
KW - derivatives
KW - Arginine analogs
KW - Biological Markers metabolism
KW - Endothelium, Vascular metabolism
KW - Enzyme Inhibitors metabolism
KW - Extracellular Matrix metabolism
KW - Nitric Oxide Synthase antagonists
KW - Raynaud Disease metabolism
KW - Regional Blood Flow physiology
KW - Scleroderma, Systemic metabolism
KW - Skin blood supply
KW - Tissue Inhibitor of Metalloproteinase-1 metabolism
M3 - SCORING: Zeitschriftenaufsatz
VL - 36
SP - 984
EP - 988
JO - J RHEUMATOL
JF - J RHEUMATOL
SN - 0315-162X
IS - 5
M1 - 5
ER -